Skip to Content
Merck
All Photos(1)

Documents

A2795

Sigma-Aldrich

N-Acetyl-D-galactosamine

≥98% (HPLC)

Synonym(s):

2-Acetamido-2-deoxy-D-galactose, D-GalNAc, N-Acetylchondrosamine

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C8H15NO6
CAS Number:
Molecular Weight:
221.21
Beilstein:
2331340
EC Number:
MDL number:
UNSPSC Code:
12352201
PubChem Substance ID:
NACRES:
NA.25

Assay

≥98% (HPLC)

form

powder

technique(s)

HPLC: suitable

color

white

mp

160 °C

solubility

water: 50 mg/mL, clear, colorless

storage temp.

2-8°C

SMILES string

CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O

InChI

1S/C8H15NO6/c1-3(11)9-5-7(13)6(12)4(2-10)15-8(5)14/h4-8,10,12-14H,2H2,1H3,(H,9,11)/t4-,5-,6+,7-,8?/m1/s1

InChI key

OVRNDRQMDRJTHS-KEWYIRBNSA-N

Looking for similar products? Visit Product Comparison Guide

General description

N-Acetyl-D-galactosamine (GalNAc), an amino sugar, is a component of many O-linked and N-linked glycan structures. As uridine diphosphate (UDP)-GalNAc, GalNAc is the initial O-linked sugar to many serine and threonine residues in protein glycosylations.

Application

N-Acetyl-D-galactosamine has been used:
  • as a Dolichos biflorus agglutinin (DBA) haptenic sugar in lectin bead binding assay
  • to assess the specificity of lectin binding using lectin blot inhibition
  • in immunohistochemistry to pre-adsorb Wisteria floribunda lectin

N-Acetyl-D-galactosamine (GalNAc), an aminosugar, is a component of many O-linked and N-linked glycan structures. As UDP-GalNAc, GalNAc is the intial O-linked sugar to many serine and threonine residues in protein glycosylations.

Other Notes

To gain a comprehensive understanding of our extensive range of Monosaccharides for your research, we encourage you to visit our Carbohydrates Category page.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Malte Lenders et al.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 32(12), 2090-2097 (2016-09-30)
Renal and cardiac involvement is responsible for substantial morbidity and mortality in Fabry disease (FD). We analysed the incidence of FD-related renal, cardiac and neurologic end points in patients with FD on long-term enzyme replacement therapy (ERT). A retrospective analysis
Dezemon Zingue et al.
Scientific reports, 8(1), 6778-6778 (2018-05-02)
Contaminations and fastidiousness of M. ulcerans may have both hamper isolation of strains from environmental sources. We aimed to optimize decontamination and culture of environmental samples to circumvent both limitations. Three strains of M. ulcerans cultured onto Middlebrook 7H10 at
David J Gill et al.
Trends in cell biology, 21(3), 149-158 (2010-12-15)
O-GalNAc glycosylation of proteins confers essential structural, protective and signaling roles in eumetazoans. Addition of O-glycans onto proteins is an extremely complex process that regulates both sites of attachment and the types of oligosaccharides added. Twenty distinct polypeptide GalNAc-transferases (GalNAc-Ts)
Ju Huang et al.
Molecular therapy. Methods & clinical development, 5, 241-258 (2017-06-13)
Fabry disease is a rare lysosomal storage disorder (LSD). We designed multiple recombinant lentivirus vectors (LVs) and tested their ability to engineer expression of human α-galactosidase A (α-gal A) in transduced Fabry patient CD34
Kai J Rogers et al.
PLoS neglected tropical diseases, 13(12), e0007819-e0007819 (2019-12-12)
Ebolavirus (EBOV) outbreaks, while sporadic, cause tremendous morbidity and mortality. No therapeutics or vaccines are currently licensed; however, a vaccine has shown promise in clinical trials. A critical step towards development of effective therapeutics is a better understanding of factors

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service